Endothelium a new target for a therapeutic action of ACE inhibitors


如何引用文章

全文:

作者简介

Yu Karpov

参考

  1. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 1991; 325: 293-302.
  2. Pfeffer M. A., Braunwald E., Moye L. A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N. Engl. J. Med. 1992; 327: 669-677.
  3. Dzau V., Bernstein K., Celermaier D. et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am. J. Cardiol. 2001; 88 (suppl. L): 1-20.
  4. Карпов Ю. А. Клинические последствия ингибирования тканевого ангиотензинпревращающего фермента: целесообразность при стабильной ИБС. Кардиология 2002; 6: 117-122.
  5. Lonn E. M., Yusuf S., Jha P. et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056-2069.
  6. Yamada H., Fabris В., Allen A. M. et al. Localization of angiotensin-converting enzyme in rat heart. Circ. Res. 1991; 68: 141-149.
  7. Falkenhahn M., Franks F., Bohle R. M. et al. Cellular distribution of angiotensin-converting enzyme after myocardial infarction. Hypertension 1995; 25: 219-226.
  8. Horning В., Kohler C., Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95: 1115-1118.
  9. Громнацкий H. И., Дюсшикеева H. Б, Влияние небиволола на ремоделирование сердца и сосудов и состояние гемодинамики у больных артериальной гипертонией. Кардиология 2002; 10: 27-30.
  10. Курбанов Р. Д., Елисеев М. Р., Турсунов Р. Р. и др. Гуморальные маркеры дисфункции эндотелия при эссенциальной гипертонии. Кардиология 2003; 7: 61-65.
  11. Mulder P., Elfertak L., Richard V. et al. Peripheral artery structure and endothelial function in heart failure: effects of angiotensin-converting enzyme inhibition. Am. J. Physiol. 1996; 271: H469-H477.
  12. Van Belle E., Meurice Т., Tio F. O. et al . ACE inhibition accelerates endothelial regrowth in vivo: a possible explanation for the benefit observed with ACE inhibitors following arterial injury. Biochem. Biophys. Res. Commun. 1997; 231: 577-581.
  13. Thybo N. K., Stephens N., Cooper A. et al. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995; 26: 716-718.
  14. Mancini G. B. J., Henry G. С., Macaya С. et al. Angiotensinconverting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94: 258-265.
  15. Anderson T. J., Elstein E., Haber H. et al. Comparative study of ACE inhibition, angiotensin All antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J. Am. Coll. Cardiol. 2000; 35: 60-66.
  16. Fogari R., Mugellini A., Zoppi A. et al. Effect of losartan and perindopril on plasma PAl-i and fibrinogen in hypertensive type 2 diabetic patients. J. Hypertens. 1999; 17 (suppl. 3): 1-34.
  17. Fogari R., Pasptto C., Zoppi A. et al. Effect of perindopril and atenolol on plasma PAI-1 in hypertensive patients with acute ischemic stroke. J. Hypertens. 2002; 20 (suppl, 4): S145.
  18. Diet F., Pratt R. E., Berry G. J. et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756-2767.
  19. Zhuo J. L., Mendelsohn F. A. O., Ohishi M. Perindopril alters angiotensin-converting enzyme, ATI receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 2002; 39 (pt 2): 634-638.
  20. Pitt В., O'Neill В., Feldman R. et al. The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved ventricular ftinction. Am. J. Cardiol. 2001; 87: 1058-1063.
  21. The HOPE Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramiprii, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N. Engl. J. Med. 2000; 342: 145-153.
  22. PROGRESS Collaborative group. Effects of a perindoprilbased blood pressure lowering regimen on cardiac outcomes among patiens with cerebrovascular disease. Eur. Heart J. 2003; 24: 475-484.
  23. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782788.
  24. Lonn E. M., Yusuf S., Dzavik V. et al. Effects of ramiprii and vitamin E on atherosclerosis. The study to evaluate carotid ultrasound changes in patients treated with ramiprii and vitamin E (SECURE). Circulation 2001; 103: 919-925.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2004

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##